Gastric Cancer
Conditions
Keywords
Gastric cancer, Helicobacter pylori, Subtotal gastrectomy, Overall survival, Metachronous cancer
Brief summary
In this study, we will observe the long-term survival rate, overall mortality rate, gastric cancer specific mortality rate, and the incidence rate of metachronous cancer in patients who received subtotal gastrectomy, with or without Helicobacter pylori eradication.
Detailed description
In this study, we will observe the long-term survival rate, overall mortality rate, gastric cancer specific mortality rate, and the incidence rate of metachronous cancer in patients who received subtotal gastrectomy, with or without Helicobacter pylori eradication. In addition, we will analyze the correlation between the incidence and survival rate of this type of stomach cancer by comparing smoking, gastric cancer direct family history, disease stage (TNM staging), the histologic type of stomach cancer (intestinal, diffuse, mixed), and the surgical method (Billoth I, Billoth II) as well as the infection and eradication status of H. pylori.
Interventions
COMBINATION_PRODUCTHelicobacter pylori eradication (combination therapy)
Antibiotic eradication therapy (triple or quadriple regimen)
Sponsors
Seoul National University Bundang Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with gastric cancer and received surgery (partial, distal, subtotal gastrectomy), and tested Helicobacter pylori status
Exclusion criteria
* Patients with other severe diseases (other primary cancer, severe cardiovascular, cerebral, renal, hepatic diseases) * Patients received palliative treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | From date of initial curative surgery for gastric cancer, until the date of death from any cause, up to 60 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Gastric cancer-specific (disease-free) survival | From date of initial curative surgery for gastric cancer, until the date of diagnosis of gastric cancer recurrence or the date of death, whichever comes first, up to 60 months | Survival period without cancer recurrence or newly developed stomach cancer diagnosis |
| Metachronous cancer (remnant stomach cancer) | Up to 60 months | The number of patients who were diagnosed with new carcinoma on the remnant stomach, over follow-up period of up to 60 months, in eradication group and non-eradication group |
Countries
South Korea
Outcome results
None listed